版本:
中国

BRIEF-OPKO receives FDA orphan drug status to treat genetic neurological disorder

March 22 OPKO Health Inc-

* OPKO receives FDA orphan drug status for its new oligonucleotide to treat genetic neurological disorder

* OPKO Health Inc says OPKO plans to initiate a clinical trial of cur-1916 for treatment of dravet syndrome this year

* Received orphan drug designation from U.S. FDA for oligonucleotide-based antagonat (cur-1916) for treatment of dravet syndrome Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐